Nurix Therapeutics (NRIX)
(Delayed Data from NSDQ)
$14.13 USD
+0.32 (2.32%)
Updated Apr 23, 2024 04:00 PM ET
After-Market: $14.12 -0.01 (-0.07%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Balance Sheet
Fiscal Year End for Nurix Therapeutics, Inc falls in the month of November.
All items in Millions except Per Share data.
11/30/2023 | 11/30/2022 | 11/30/2021 | 11/30/2020 | 11/30/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 288 | 309 | 296 | 281 | 38 |
Receivables | 0 | 0 | 6 | 4 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 8 | 9 | 9 | 13 | 2 |
Total Current Assets | 296 | 318 | 311 | 298 | 39 |
Net Property & Equipment | 17 | 17 | 11 | 7 | 4 |
Investments & Advances | 7 | 64 | 137 | 91 | 1 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 5 | 5 | 3 | 0 | 0 |
Total Assets | 356 | 417 | 477 | 396 | 44 |
Liabilities & Shareholders Equity | 11/30/2023 | 11/30/2022 | 11/30/2021 | 11/30/2020 | 11/30/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 6 | 5 | 7 | 3 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 25 | 22 | 15 | 8 | 5 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 48 | 38 | 41 | 33 | 10 |
Total Current Liabilities | 87 | 71 | 66 | 45 | 16 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 45 | 36 | 59 | 61 | 36 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 1 | 2 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 48 |
Total Liabilities | 155 | 113 | 134 | 106 | 102 |
Shareholders Equity | 11/30/2023 | 11/30/2022 | 11/30/2021 | 11/30/2020 | 11/30/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 746 | 709 | 564 | 394 | 3 |
Retained Earnings | -545 | -401 | -221 | -104 | -60 |
Other Equity | -1 | -4 | -1 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 200 | 304 | 342 | 290 | -58 |
Total Liabilities & Shareholder's Equity | 356 | 417 | 477 | 396 | 44 |
Total Common Equity | 200 | 304 | 342 | 290 | -58 |
Shares Outstanding | 48.50 | 47.10 | 44.60 | 38.80 | NA |
Book Value Per Share | 4.13 | 6.45 | 7.67 | 7.48 | 0.00 |
Fiscal Year End for Nurix Therapeutics, Inc falls in the month of November.
All items in Millions except Per Share data.
2/29/2024 | 11/30/2023 | 8/31/2023 | 5/31/2023 | 2/28/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 244 | 288 | 259 | 281 | 277 |
Receivables | 0 | 0 | 2 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 7 | 8 | 7 | 9 | 11 |
Total Current Assets | 251 | 296 | 268 | 290 | 288 |
Net Property & Equipment | 18 | 17 | 17 | 19 | 18 |
Investments & Advances | 10 | 7 | 10 | 27 | 48 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 4 | 5 | 5 | 5 | 5 |
Total Assets | 313 | 356 | 308 | 351 | 370 |
Liabilities & Shareholders Equity | 2/29/2024 | 11/30/2023 | 8/31/2023 | 5/31/2023 | 2/28/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 6 | 6 | 2 | 5 | 6 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 28 | 25 | 22 | 18 | 15 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 46 | 48 | 32 | 44 | 38 |
Total Current Liabilities | 88 | 87 | 61 | 72 | 65 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 34 | 45 | 10 | 15 | 26 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 144 | 155 | 74 | 91 | 96 |
Shareholders Equity | 2/29/2024 | 11/30/2023 | 8/31/2023 | 5/31/2023 | 2/28/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 756 | 746 | 738 | 728 | 719 |
Retained Earnings | -587 | -545 | -503 | -466 | -442 |
Other Equity | 0 | -1 | -1 | -2 | -3 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 169 | 200 | 234 | 260 | 274 |
Total Liabilities & Shareholder's Equity | 313 | 356 | 308 | 351 | 370 |
Total Common Equity | 169 | 200 | 234 | 260 | 274 |
Shares Outstanding | 49.10 | 48.50 | 48.20 | 47.40 | 47.40 |
Book Value Per Share | 3.44 | 4.13 | 4.85 | 5.48 | 5.78 |